Serotherapy in paediatric allogeneic stem cell transplantation: comparison of ATG and Campath-1H as part of conditioning

被引：0
|
作者：
Jol-van der Zijde, C. M. [1 ]
Jansen-Hoogendijk, A. M. [1 ]
Egeler, R. [1 ]
Lankester, A. C. [1 ]
Bredius, R. G. M. [1 ]
van Tol, M. J. D. [1 ]
机构：
[1] Leiden Univ, Med Ctr, Leiden, NL, Netherlands
来源：
BONE MARROW TRANSPLANTATION | 2009年 / 43卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：S126 / S126
页数：1
相关论文
共 50 条
  • [31] Campath-1H in intestinal and multivisceral transplantation: Preliminary data
    Tzakis, AG
    Kato, T
    Nishida, S
    Levi, D
    Madariaga, J
    De Faria, W
    Nery, J
    Neff, G
    Kirk, AD
    Ruiz, P
    TRANSPLANTATION PROCEEDINGS, 2002, 34 (03) : 937 - 937
  • [32] Campath-1H in renal transplantation: The University of Wisconsin experience
    Knechtle, SJ
    Fernandez, LA
    Pirsch, JD
    Becker, BN
    Chin, LT
    Becker, YT
    Odorico, JS
    D'Alessandro, AM
    Sollinger, HW
    SURGERY, 2004, 136 (04) : 754 - 759
  • [33] ATG in paediatric haemopoietic stem cell transplantation
    Diaz, Miguel A.
    Vicent, Marta G.
    LANCET HAEMATOLOGY, 2015, 2 (05): : E178 - E179
  • [34] Late events in reduced-intensity allogeneic haematopoietic stem cell transplantation (HSCT) with alemtuzumab (CAMPATH-1H) containing regimens impact on outcome compared with standard myeloablative conditioning.
    Ho, AYL
    Kenyon, M
    Parker, JE
    El-Hemaidi, I
    Zuckerman, M
    Devereux, S
    Pagliuca, A
    Mufti, GJ
    BLOOD, 2002, 100 (11) : 414A - 414A
  • [35] Alemtuzumab (Campath-1H)-Induced Coagulopathy in Renal Transplantation
    Farid, Shahid G.
    Barwick, Joe
    Goldsmith, Paul J.
    Ahmad, Niaz
    Newstead, Charles
    Baker, Richard
    TRANSPLANTATION, 2009, 87 (11) : 1751 - 1751
  • [36] Alemtuzumab (Campath-1H): A systematic review in organ transplantation
    Morris, Peter J.
    Russell, Neil K.
    TRANSPLANTATION, 2006, 81 (10) : 1361 - 1367
  • [37] In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation
    Kottaridis, PD
    Milligan, DW
    Chopra, R
    Chakraverty, RK
    Chakrabarti, S
    Robinson, S
    Peggs, K
    Verfuerth, S
    Pettengell, R
    Marsh, JCW
    Schey, S
    Mahendra, P
    Morgan, GJ
    Hale, G
    Waldmann, H
    de Elvira, MCR
    Williams, CD
    Devereux, S
    Linch, DC
    Goldstone, AH
    Mackinnon, S
    BLOOD, 2000, 96 (07) : 2419 - 2425
  • [38] Treatment with campath-1H for relapsed chronic lymphocytic leukemia after allogeneic peripheral blood stem cell transplantation does not abrogate the development of chronic GVHD
    Wolff, D
    Steiner, B
    Stilgenbauer, S
    Kahl, C
    Leithäuser, M
    Junghanss, C
    Wilhelm, S
    Kleine, HD
    Zimmermann, R
    Hartung, G
    Casper, J
    Freund, M
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2004, 72 (02) : 145 - 148
  • [39] Campath-1H induction therapy in kidney transplantation.
    Kaufman, DB
    Leventhal, JR
    Gallon, LG
    Parker, MA
    Stuart, FP
    AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 : 157 - 157
  • [40] The evolving role of alemtuzumab (Campath-1H) in renal transplantation
    Pham, Phuong-Thu T.
    Lipshutz, Gerald S.
    Pham, Phuong-Truc T.
    Kawahji, Joseph
    Singer, Jennifer S.
    Pham, Phuong-Chi T.
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2008, 3 : 41 - 49
12345